Radiopharm Theranostics Limited (RAD) Price & Analysis

Compare

18 Followers

RAD Stock Chart & Stats

Day’s Range― - ―

52-Week RangeAU$0.02 - AU$0.05

Previous CloseN/A

Volume5.13M

Average Volume (3M)2.60M

Market Cap

AU$56.02M

Enterprise ValueAU$18.63M

Total Cash (Recent Filing)AU$36.44M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.28

Next Earnings

Sep 25, 2025

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding2,333,980,200

10 Day Avg. Volume2,473,372

30 Day Avg. Volume2,595,521

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio-1.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.05

Price Target Upside66.67% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Radiopharm Theranostics Limited News

PremiumThe Fly

Radiopharm granted U.S. FDA FTD for RAD101

2d ago

RADX

PremiumThe Fly

Radiopharm announces dosing of first patient in Phase 1 HEAT trial

9d ago

RADX

PremiumThe Fly

Radiopharm reports preclinical Lu177-B7H3-mAb data

11d ago

RADX

PremiumThe Fly

Radiopharm pipeline ‘dramatically’ undervalued, says JonesResearch

22d ago

RADX

PremiumThe Fly

Radiopharm, ITM sign supply agreement for n.c.a. Lutetium-177

25d ago

RADX

PremiumCompany Announcements

Radiopharm Theranostics Issues New Shares, Ensures Compliance

2d ago

RAD

PremiumCompany Announcements

Radiopharm Theranostics Expands Market Presence with New ASX Quotation

2d ago

RAD

PremiumCompany Announcements

Radiopharm Theranostics’ RAD 101 Receives FDA Fast Track Designation

3d ago

RAD

See All AU:RAD News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe advancement of RAD 204 into a first-in-human Phase I trial in non-small cell lung cancer is a significant development for Radiopharm Theranostics.

Market StrategyThe launch of American Depository Shares, with plans for a secondary listing on Nasdaq, positions Radiopharm for broader market exposure.

Therapeutic PipelineRadiopharm Theranostics has focused its therapeutic pipeline on biologically validated targets that have seen limited or no use in radiopharmaceuticals, which is designed to de-risk development and limit competition.

Bears Say

Capital RaiseThe AUD 70M capital raise resulted in higher dilution than previously estimated due to associated lower prices.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

8.26% Insiders

―

Mutual Funds

― Other Institutional Investors

91.74% Public Companies and

Individual Investors

Detailed Ownership Overview >

RAD FAQ

What was Radiopharm Theranostics Limited’s price range in the past 12 months?

Radiopharm Theranostics Limited lowest share price was AU$0.02 and its highest was AU$0.05 in the past 12 months.

What is Radiopharm Theranostics Limited’s market cap?

Radiopharm Theranostics Limited’s market cap is AU$56.02M.

When is Radiopharm Theranostics Limited’s upcoming earnings report date?

Radiopharm Theranostics Limited’s upcoming earnings report date is Sep 25, 2025 which is in 104 days.

How were Radiopharm Theranostics Limited’s earnings last quarter?

Radiopharm Theranostics Limited released its earnings results on Feb 28, 2025. The company reported -AU$0.01 earnings per share for the quarter, the consensus estimate of -AU$0.01 by AU$0.

Is Radiopharm Theranostics Limited overvalued?

According to Wall Street analysts Radiopharm Theranostics Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Radiopharm Theranostics Limited pay dividends?

Radiopharm Theranostics Limited does not currently pay dividends.

What is Radiopharm Theranostics Limited’s EPS estimate?

Radiopharm Theranostics Limited’s EPS estimate is -0.01.

How many shares outstanding does Radiopharm Theranostics Limited have?

Radiopharm Theranostics Limited has 2,333,980,200 shares outstanding.

What happened to Radiopharm Theranostics Limited’s price movement after its last earnings report?

Radiopharm Theranostics Limited reported an EPS of -AU$0.01 in its last earnings report, expectations of -AU$0.01. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Radiopharm Theranostics Limited?

Currently, no hedge funds are holding shares in AU:RAD

Radiopharm Theranostics Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-108.26%

Trailing 12-Months

Asset Growth

46.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Radiopharm Theranostics Limited

Radiopharm Theranostics Limited (RAD) is a biotechnology company focused on the development and commercialization of radiopharmaceutical products for both diagnostic and therapeutic use in the field of oncology. The company leverages advanced medical imaging and targeted radiotherapy technologies to create innovative solutions that improve cancer diagnosis and treatment outcomes. By integrating theranostics, which combines therapeutic and diagnostic capabilities, Radiopharm aims to enhance the precision and effectiveness of cancer care.

RAD Stock 12 Month Forecast

Average Price Target

AU$0.05

▲(66.67%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.05</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"Jun<br/>2023","9":"Sep<br/>2024","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.03,0.031538461538461536,0.03307692307692307,0.03461538461538462,0.036153846153846154,0.03769230769230769,0.03923076923076923,0.040769230769230766,0.04230769230769231,0.04384615384615385,0.045384615384615384,0.04692307692307693,0.04846153846153846,{"y":0.05,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.03,0.031538461538461536,0.03307692307692307,0.03461538461538462,0.036153846153846154,0.03769230769230769,0.03923076923076923,0.040769230769230766,0.04230769230769231,0.04384615384615385,0.045384615384615384,0.04692307692307693,0.04846153846153846,{"y":0.05,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.03,0.031538461538461536,0.03307692307692307,0.03461538461538462,0.036153846153846154,0.03769230769230769,0.03923076923076923,0.040769230769230766,0.04230769230769231,0.04384615384615385,0.045384615384615384,0.04692307692307693,0.04846153846153846,{"y":0.05,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.11,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.15,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.13,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.07,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >